antibiotic/diarrhea

FIELD OF THE INVENTION This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC). More specifically, the invention concerns neutralization of C. difficile toxin A associated with

TECHNICAL FIELD This invention relates to the treatment or prophylaxis of conditions resulting from the accumulation of acid in the gastrointestinal tract of a human or an animal, said accumulation resulting from the fermentation of carbohydrate in the gastrointestinal tract of the human or animal.

FIELD OF INVENTION The present invention relates generally to methods of treating disorders such as AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer

TECHNICAL FIELD The present invention relates generally to a method of preventing diarrhea associated with infectious agents such as rotavirus, or diarrhea associated with antibiotic therapies. More specifically, this invention relates to a powdered infant nutritional that contains the probiotic

BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

BACKGROUND OF THE INVENTION Field of the Invention This invention relates to the treatment of diarrhea and related conditions caused by pathogenic E. coli infection. More specifically, this invention is drawn to the unexpected discovery that by administering a composition which binds and removes the

FIELD OF THE INVENTION The present invention relates to the use of lactic bacteria strains in the prevention of diarrhea. More particularly, the present invention concerns the use of lactic bacteria in order to prevent antibiotic associated diarrhea (AAD). DESCRIPTION OF PRIOR ART Diarrhea may be

FIELD OF INVENTION The invention belongs to the field of animal and poultry feeds, and in particular, relates to non-antibiotic feeds. BACKGROUND China has the largest capacity in the world in poultry meat production. 71% of all poultry meat consumed in China is chicken. With concepts of food

FIELD OF THE INVENTION The present invention relates to 5-ASA derivatives and methods of treating diseases therewith. BACKGROUND OF THE INVENTION Many people suffer from inflammatory bowel disease (IBD). TRD is a generic term used to refer to two inflammatory diseases, ulcerative colitis and Crohn's

FIELD OF THE INVENTION The present invention relates to the development of platform technology for targeted, controlled delivery of oral enhanced probiotics for various indications, including for example the active and prophylaxis treatment of Clostridium difficile Infection as well as Metabolic

FIELD OF THE INVENTION The present invention relates to the development of platform technology for targeted, controlled delivery of oral enhanced probiotics for various indications, including for example the active and prophylaxis treatment of Clostridium difficile Infection as well as Metabolic

FIELD OF THE INVENTION This invention relates to an oral rehydration solution containing indigestible oligosaccharides for the inhibition of disease states associated with Clostridium difficile. BACKGROUND OF INVENTION The successful management of acute diarrhea is still a challenge today. Acute

FIELD OF THE INVENTION This invention relates to the use of indigestible oligosaccharides in the inhibition of disease states by Clostridium difficile. BACKGROUND OF INVENTION Clostridium difficile (C. difficile) is the leading known cause of nosocomial infections. Greenough et al., "Diarrhea in the